SPTX
SPTX
Seaport Therapeutics, Inc. Common StockIncome Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q1-2026 | $0 | $27.54M | $-25.41M | 0% | $-0.48 | $-27.19M |
What's going well?
The company is investing significantly in research and development, which could lead to future products or breakthroughs. Interest income and other income helped reduce the loss slightly.
What's concerning?
There was no revenue this quarter, but expenses remain high, especially for R&D and overhead. The company is burning cash with no sales to show for it, which is risky if this continues.
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q1-2026 | $182.6M | $227.67M | $343.29M | $-115.62M |
What's financially strong about this company?
The company has a huge cash and investment cushion, very little debt, and almost all assets are high quality and easy to access. Liquidity is excellent, so it can cover its bills easily.
What are the financial risks or weaknesses?
Shareholder equity is deeply negative, meaning the company owes much more than it owns. Retained losses are large, which suggests a long history of unprofitability and could make future funding harder.
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q1-2026 | $-25.41M | $-20.17M | $27.85M | $-783K | $6.87M | $-20.17M |
What's strong about this company's cash flow?
The company still has $53.4 million in cash, and working capital changes helped cash flow this quarter. No debt means less financial risk for now.
What are the cash flow concerns?
SPTX is losing real cash from its core business, with a $20.2 million operating cash burn and no sign of self-sustaining operations. The company is funding itself by selling investments, which can't last forever.
5-Year Trend Analysis
A comprehensive look at Seaport Therapeutics, Inc. Common Stock's financial evolution and strategic trajectory over the past five years.
SPTX combines strong near-term liquidity and low traditional debt with a clear scientific focus on neuropsychiatric disorders and a proprietary delivery platform that could differentiate its drugs. The cost structure is concentrated on R&D rather than overhead, and early clinical signals from the lead candidate support the technical rationale behind the Glyph platform. Overall, the company is positioned as an innovation-driven, platform-based biotech with meaningful cash resources to pursue its current plans.
The main risks stem from the absence of revenue, substantial ongoing losses, and heavy negative cash flow, all layered on top of a balance sheet with negative equity. Scientific, clinical, and regulatory uncertainties are significant, particularly because much of the company’s value is tied to a single core technology and a limited number of early-stage programs. Continued dependence on capital markets or partners to fund operations, along with competition from larger and better-funded CNS players, adds further uncertainty.
The outlook for SPTX is highly dependent on clinical progress and financing conditions. In the near term, the company appears to have sufficient liquidity to advance its key programs and generate additional data. Over the medium to long term, the trajectory will hinge on whether the Glyph platform can produce clearly differentiated treatments, attract strategic partners, and eventually support a transition toward a more sustainable business model with recurring revenue. The range of potential outcomes is wide, reflecting both the promise of the technology and the inherent volatility of early-stage biotechnology.
About Seaport Therapeutics, Inc. Common Stock
https://www.seaporttx.comSeaport Therapeutics, Inc. is a developing biopharmaceutical enterprise currently undergoing clinical trials, focused on creating groundbreaking treatments for neuropsychiatric conditions. The company is primarily engaged in tackling disorders like depression and anxiety, utilizing its unique Glyph technology.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q1-2026 | $0 | $27.54M | $-25.41M | 0% | $-0.48 | $-27.19M |
What's going well?
The company is investing significantly in research and development, which could lead to future products or breakthroughs. Interest income and other income helped reduce the loss slightly.
What's concerning?
There was no revenue this quarter, but expenses remain high, especially for R&D and overhead. The company is burning cash with no sales to show for it, which is risky if this continues.
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q1-2026 | $182.6M | $227.67M | $343.29M | $-115.62M |
What's financially strong about this company?
The company has a huge cash and investment cushion, very little debt, and almost all assets are high quality and easy to access. Liquidity is excellent, so it can cover its bills easily.
What are the financial risks or weaknesses?
Shareholder equity is deeply negative, meaning the company owes much more than it owns. Retained losses are large, which suggests a long history of unprofitability and could make future funding harder.
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q1-2026 | $-25.41M | $-20.17M | $27.85M | $-783K | $6.87M | $-20.17M |
What's strong about this company's cash flow?
The company still has $53.4 million in cash, and working capital changes helped cash flow this quarter. No debt means less financial risk for now.
What are the cash flow concerns?
SPTX is losing real cash from its core business, with a $20.2 million operating cash burn and no sign of self-sustaining operations. The company is funding itself by selling investments, which can't last forever.
5-Year Trend Analysis
A comprehensive look at Seaport Therapeutics, Inc. Common Stock's financial evolution and strategic trajectory over the past five years.
SPTX combines strong near-term liquidity and low traditional debt with a clear scientific focus on neuropsychiatric disorders and a proprietary delivery platform that could differentiate its drugs. The cost structure is concentrated on R&D rather than overhead, and early clinical signals from the lead candidate support the technical rationale behind the Glyph platform. Overall, the company is positioned as an innovation-driven, platform-based biotech with meaningful cash resources to pursue its current plans.
The main risks stem from the absence of revenue, substantial ongoing losses, and heavy negative cash flow, all layered on top of a balance sheet with negative equity. Scientific, clinical, and regulatory uncertainties are significant, particularly because much of the company’s value is tied to a single core technology and a limited number of early-stage programs. Continued dependence on capital markets or partners to fund operations, along with competition from larger and better-funded CNS players, adds further uncertainty.
The outlook for SPTX is highly dependent on clinical progress and financing conditions. In the near term, the company appears to have sufficient liquidity to advance its key programs and generate additional data. Over the medium to long term, the trajectory will hinge on whether the Glyph platform can produce clearly differentiated treatments, attract strategic partners, and eventually support a transition toward a more sustainable business model with recurring revenue. The range of potential outcomes is wide, reflecting both the promise of the technology and the inherent volatility of early-stage biotechnology.
CEO
Daphne Zohar
Compensation Summary
(Year )
Upcoming Earnings
ETFs Holding This Stock
Summary
Showing Top 3 of 19
Ratings Snapshot
Rating : C+